Compare AVAV & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | KRYS |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.6B |
| IPO Year | 2006 | 2017 |
| Metric | AVAV | KRYS |
|---|---|---|
| Price | $144.32 | $356.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $316.88 | $297.60 |
| AVG Volume (30 Days) | ★ 1.2M | 184.9K |
| Earning Date | 03-10-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 3.62 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $135.55 | $38.74 |
| Revenue Next Year | $14.90 | $32.53 |
| P/E Ratio | ★ N/A | $102.13 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $135.20 | $145.46 |
| 52 Week High | $417.86 | $382.54 |
| Indicator | AVAV | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 62.80 |
| Support Level | $138.24 | $253.89 |
| Resistance Level | $162.30 | $382.33 |
| Average True Range (ATR) | 7.81 | 10.15 |
| MACD | -2.80 | 3.30 |
| Stochastic Oscillator | 7.54 | 91.64 |
AeroVironment Inc is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploys autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. The company operates business in two reportable segments: Autonomous Systems (AxS) and Space, Cyber and Directed Energy (SCDE). It derives majority of revenue from Autonomous Systems segment focuses on the design, development, production, delivery, and support of intelligent, multi-domain robotic systems, including UAS, uncrewed underwater vehicles and ground robot systems. Geographically it derives the majority of revenue from domestic operations.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.